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C. THE CANNABIS MARKET 
Cannabis production remains  
a global phenomenon
Cannabis plant cultivation — either through direct 
indicators (cultivation or eradication of cannabis 
plants) or indirect indicators (seizures of cannabis 
plants, domestic cannabis production being indi-
cated as the source of seizures, etc.) — was reported 
on the territory of 135 countries in the period 2010-
2015, covering 92 per cent of the world population. 
Given the absence of systematic measurements, how-
ever, the extent and trends in cannabis cultivation 
and production are difficult to assess. Most indirect 
indicators come from law enforcement authorities 
and, to a certain extent, reflect their priorities and 
resources.47 
Morocco remains the country most reported by 
Member States as the source of cannabis resin, fol-
lowed by Afghanistan and, to a lesser extent, 
Lebanon, India and Pakistan. In contrast to traf-
ficking in cannabis resin, which is not only 
intraregional but also interregional (notably, traf-
ficking from North Africa to Europe), trafficking 
in cannabis herb continues to be largely intrare-
gional. Thus, it is more useful to identify the 
countries most frequently reported at the regional 
level as countries of origin over the period 2010-
2015 (see box). 
47  For more details, see World Drug Report 2015, box on 
“Interpreting drug seizures”, p. 27.
Global  number of  users
change from previous year
G lobal  se izures
1,536
tons
cannabis resin
5,781
tons
6%
herb resin
-2%
cannabis herb
20152015
183 million
Note: Data refer to 2015. Estimates of illicit cultivation, production and eradication of cannabis and prevalence of cannabis use are avail-
able in the annex of booklet 2.
Countries most frequently 
reported as countries of 
origin of cannabis herb, by 
region/subregion, 2010-2015
 • The most often reported source country for 
transnational shipments in North America was 
Mexico, followed by Canada. Although this 
does not mean that Mexico is the largest  
producer of cannabis in North America.  
Significant amounts of cannabis herb are 
 produced in the United States, though mostly 
for domestic consumption and not for export. 
 • In South America, the Caribbean and Central 
America, the most frequently reported source 
countries of cannabis herb were Colombia and 
Paraguay, followed by Jamaica. 
 • In Africa, the most frequently reported source 
countries were Nigeria, Mozambique, Ghana 
and Swaziland, although it is difficult to 
identify specific countries in Africa, because a 
number of other countries were also reported. 
 • In Asia, the most frequently identified source 
country was Afghanistan, followed by Kyr-
gyzstan, Myanmar, the Lao People’s Democrat-
ic Republic, Lebanon, India and Nepal. 
 • In Europe, the two most frequently mentioned 
source countries for cross-border trafficking 
of cannabis herb were the Netherlands and 
Albania. 
Source: UNODC, based on responses to the annual 
report questionnaire.
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Cannabis trafficking
Based on quantities intercepted, the trafficking of 
cannabis seems to have stabilized at a high level in 
the past decade (compared with the level in the late 
1990s). Over the period 2010-2015, quantities of 
herbal cannabis seized were more than four times 
those of cannabis resin, with some 6,000 tons of 
cannabis herb and 1,300 tons of cannabis resin inter-
cepted annually. In 2015, the largest cannabis herb 
seizures worldwide were reported by Mexico, fol-
lowed by the United States, Nigeria, Paraguay and 
Egypt; the largest cannabis resin seizures were 
reported by Spain, Pakistan and Morocco, followed 
by Afghanistan and Algeria. 
Eradication as an indicator of cannabis production
Measuring the extent of eradication is challenging because 
some countries report eradication in terms of hectares, while 
others report in terms of numbers of cannabis plants eradi-
cated, weight of cannabis plants seized or number of cannabis 
cultivation sites eradicated. This makes comparisons of eradi-
cation difficult. 
The largest areas of eradicated cannabis cultivation over 
the period 2010-2015 were reported by Mexico, followed 
by Morocco and Nigeria. The largest numbers of cannabis 
cultivation sites eradicated were reported by the United 
States, followed by Ukraine, the Netherlands and the Russian 
Federation. The largest numbers of cannabis plants eradicated 
were reported by Nigeria, followed by the United States, the 
Philippines and Paraguay. Finally, the largest quantities of 
cannabis plants seized were reported by Bolivia (Plurinational 
State of) and Peru, followed by Jamaica. 
The combination of the various indicators suggests that the 
world’s largest areas of cannabis cultivation subjected to 
eradication over the period 2010-2015 were located in the 
Americas. This may indicate the global predominance of that 
region in cannabis cultivation, but may also point to the extent 
to which law enforcement authorities have been prioritiz-
ing the eradication of cannabis 
cultivation, which could also 
have played a role. The second 
largest area of cannabis culti-
vation eradicated was in Africa, 
followed by Asia and Europe, 
then Oceania. The average dis-
tribution of cannabis eradication 
turns out to be quite similar to 
that of overall cannabis herb 
and resin seizures reported at 
the global level over the period 
2010-2015. Patterns of cultiva-
tion may differ from patterns of 
law enforcement operations tar-
geting cannabis cultivation; in 
Africa, in particular, where law 
enforcement capabilities are 
quite modest, the importance 
of cannabis cultivation may be 
greater than that indicated by 
the extent of eradication and 
seizures.
Fig. 22 Global quantities of cannabis resin and 
herb seized, 1998-2015
Source: UNODC, based on responses to the annual report 
questionnaire. 
Available indicators of the distribution of eradication of cannabis  
production, by region, 2010-2015
Source: UNODC calculations, based on responses to the annual report questionnaire. 
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rising levels of cannabis consumption), reflecting a 
possible fall in cannabis production in Mexico,48 as 
well as an overall reduction in the priority given to 
cannabis interdiction as the cultivation, production, 
trade and consumption of cannabis has become legal 
in several jurisdictions in the United States in recent 
years. 
By contrast, cannabis herb seizures more than dou-
bled over the period 2010-2015 in Africa and South 
America. Meanwhile, cannabis herb seizures 
48 This is in line with a decline in cannabis eradication 
reported by Mexico and, more importantly, with falling  
cannabis herb seizures along the Mexico-United States 
border over the period 2010-2015. While seizures of most 
drugs along that border have increased in recent years, can-
nabis herb seizures, in terms of both quantities and number 
of seizure cases, fell significantly between 2010 and 2015. 
Quantities of cannabis herb seized along the Mexico-United 
States border fell from more than 1,300 tons in 2010 
to 900 tons in 2015 (United States Drug Enforcement 
Administration, 2016 National Drug Threat Assessment, p. 
135). Note that none of the states bordering Mexico had 
legalized cannabis over the period 2010-2015 and that can-
nabis continues to be prohibited at the federal level in the 
United States, which suggests that reduced seizures along 
the Mexico-United States border may have been the result 
of lower trafficking flows of cannabis herb from Mexico to 
the United States. 
The Americas, followed by Africa,  
continue to report the majority of  
cannabis herb seizures 
In 2015, almost two thirds (64 per cent) of the total 
quantity of cannabis herb seized worldwide was 
seized in the Americas, most notably in Mexico, 
followed by the United States, Paraguay and Brazil. 
Accounting for more than a quarter (28 per cent) 
of the global total, the second largest seizures of 
cannabis herb were reported in Africa, mostly in 
Nigeria, Egypt and Morocco. Asia accounted for 5 
per cent of the total quantity of cannabis herb inter-
cepted worldwide in 2015, most of which was seized 
by India, followed by Bangladesh, Kazakhstan, Indo-
nesia and Thailand; 3 per cent of the total was seized 
in Europe, mostly by Turkey, followed by the United 
Kingdom, the Russian Federation, Spain and the 
Netherlands; and 0.1 per cent of the total was seized 
in Oceania, mostly in Australia. 
The subregion reporting the largest quantity of can-
nabis herb seized in 2015 remained North America 
(39 per cent of global seizures). Following a peak in 
2010, however, seizures of cannabis herb in North 
America declined by 55 per cent up to 2015 (despite 
Fig. 23 Global quantities of cannabis seized, annual average, by product and by country,  
2010-2015
Source: UNODC, based on responses to the annual report questionnaire.
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with seizures mostly reported by Spain, followed by 
Italy and France), while 26 per cent of the global 
total was seized by countries in North Africa (most 
notably Morocco, followed by Algeria and Egypt). 
In contrast to the slight decline in seizures of can-
nabis herb worldwide over the period 2010-2015, 
cannabis resin seizures actually increased, reflecting 
a twofold increase in interceptions in North Africa 
and substantial increases (78 per cent) in the Near 
and Middle East/South-West Asia. The opposite 
was observed in Europe, however, where the overall 
quantity of cannabis resin seized, as a proportion of 
the global total, declined from 77 per cent in 1998 
to 53 per cent in 2010 and 35 per cent in 2015. 
This decline primarily reflects the falling market 
share of cannabis resin in the European cannabis 
market as cannabis herb, mostly from domestic 
European production, has been gaining in 
popularity. 
Cannabis resin mainly continues to be smuggled 
from Morocco to Europe and to other countries in 
North Africa, as well as from Afghanistan to neigh-
bouring countries, particularly Pakistan and the 
Islamic Republic of Iran. It also seems that cannabis 
resin produced in Lebanon supplies markets in other 
remained relatively stable in Asia and in Europe, 
with increases and decreases of less than 15 per cent. 
The main sources of cannabis herb in Europe are 
within the region itself, most notably the Nether-
lands and Albania, although the European Police 
Office (Europol) has also identified Czechia as an 
important distribution hub for cannabis herb traf-
ficked to neighbouring countries.49
The largest quantities of cannabis resin 
intercepted continue to be reported in 
West and Central Europe, the Near and 
Middle East/South-West Asia and North 
Africa 
In most years of the past two decades, the largest 
seizures of cannabis resin have been reported in 
Western and Central Europe. In 2015, however, at 
38 per cent of the global total, the largest amount 
of seizures of cannabis resin took place in the Near 
and Middle East/South-West Asia, most notably in 
Pakistan, Afghanistan and Iran (Islamic Republic 
of ). The next largest seizures of cannabis resin took 
place in Western and Central Europe (35 per cent; 
49 Europol, SOCTA 2017: European Union Serious and  
Organized Crime Threat Assessment, p. 36.
Fig. 24 Quantities of cannabis herb seized, by 
region/subregion, 1998-2015
Sources: UNODC, responses to the annual report question-
naire; and government reports.
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selected subregion, 1998-2015
Sources: UNODC, responses to the annual report question-
naire; and government reports.
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49.2 million (or 7.5 per cent of the population aged 
15-64 years) in 2015. The rise in cannabis use 
appears to have been most pronounced in the United 
States, where, following some marginal declines in 
the prevalence of cannabis use between 2002 and 
2007, the annual prevalence of cannabis use 
increased (by 34 per cent) to 13.5 per cent of the 
population aged 12 years and older over the period 
2007-2015. This resulted in an overall increase of 
43 per cent in the number of past-year cannabis 
countries in the Near and Middle East, most nota-
bly the Syrian Arab Republic, Jordan and Israel, as 
well as markets in Egypt, Cyprus and Turkey. 
In addition to ongoing direct shipments of cannabis 
resin from Morocco to Spain and subsequent ship-
ments by land to France, Italy and the Netherlands, 
for further distribution to other European countries, 
Europol has reported an emerging trafficking route 
from Morocco to Libya (either by sea or by land) 
and then on to Italy. Although both UNODC and 
Europol data estimate that most of the cannabis 
resin found in Europe continues to originate in 
Morocco, it seems that Afghan cannabis resin is also 
trafficked to Europe, often using Albania as a first 
distribution hub.50 
Cannabis use has remained quite 
stable at the global level in recent 
years, despite indications that it con-
tinues to increase in Africa and Asia
Equivalent to an estimated 183 million annual users 
in 2015 (range: 128-238 million), roughly 3.8 per 
cent of the global population (2.7-4.9 per cent) used 
cannabis in the past year. This proportion has not 
changed over the past decade and is only slightly 
higher than the prevalence of cannabis use estimated 
for 1998 (3.4 per cent). Nonetheless, as the world 
population has grown, so has the number of can-
nabis users (by 28 per cent since 1998). Analysis of 
the perception of changes in drug use, as reported 
by Member States, also suggests an increase in the 
number of cannabis users, although the increase 
appears to have slowed down since 2010. Cannabis 
use in Africa and in Asia, however, are perceived to 
have continued to increase relatively rapidly in the 
past five years. 
Cannabis use continues to increase in 
North America
Data on the prevalence of cannabis use and expert 
perceptions suggest that cannabis use has been rising 
over the past decade in the Americas. UNODC esti-
mates for the Americas show an increase from 37.6 
million people (or 6.5 per cent of the population 
aged 15-64 years) who used cannabis in 200551 to 
50  Ibid., pp. 35 and 36.
51 World Drug Report 2007 (United Nations publications, 
Sales No. E.07.XI.5), p. 114.
Fig. 26 Estimated number of cannabis users and  
cannabis use perception index,1998-2015
Source: UNODC calculations based on responses to the annual reports 
questionnaire. 
Note: For details of the calculation methods, see the online methodology  
section of the present report.
-1,250
-1,000
-750
-500
-250
0
250
500
750
1,000
1,250
0
50
100
150
200
250
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Ca
nn
ab
is
 u
se
 p
er
ce
pt
io
n 
in
de
x 
(1
99
8 
= 
0)
N
um
be
r o
f c
an
na
bi
s 
us
er
s (
m
ill
io
ns
)
Cannabis users
Cannabis use perception index
Fig. 27 Cannabis use perception index, by 
region, 2010-2015
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Cannabis use trends in Europe
The average past-year prevalence of cannabis use 
among the general population (aged 15-64 years) 
has remained stable over the past decade in the Euro-
pean Union member States, at around 6.6 per cent. 
However, at an annual prevalence of 13.3 per cent, 
cannabis use remains much higher among young 
people aged 15-34 years.56 Around 3 million adults 
(1 per cent) in the European Union member States 
are estimated to be daily or near daily cannabis users, 
70 per cent of whom are between 15 and 34 year 
of age and mostly male. 
In the three countries with a high-prevalence of 
cannabis use, Germany, Spain and the United 
Kingdom (England and Wales), cannabis use has 
remained stable, while Denmark and France have 
experienced an increase in cannabis use. Many 
countries in Europe with historically low prevalence 
56 EMCDDA, European Drug Report: Trends and Developments 
2016, (2016 Luxembourg, Publications Office of the Euro-
pean Union, 2016). 
users, and of 54 per cent in the number of past-
month users.52 The major expansion in cannabis 
use across the United States has been the increase 
in regular and heavy cannabis users: the prevalence 
of daily or nearly daily use of cannabis among adults 
almost doubled from 1.9 per cent in 2002 to 3.5 
per cent in 2015, and the number of daily or near-
daily cannabis users grew by 67 per cent over the 
period 2007-2015. 
Since 2002, the major increase in past-month can-
nabis use has been observed among those aged 26 
years and older. An increase in the number of new 
initiates has also been seen among the older age 
groups, especially those aged 26 years and older. 
The high prevalence and frequency of cannabis use 
observed among adults in the United States has been 
associated with those who perceive no risk of harm 
from cannabis smoking; with those from lower 
socioeconomic groups with no more than a high 
school diploma, without health insurance, and in 
part-time employment; those who are unable to 
work due to disability; those who are unemployed; 
and those who consider that the state in which they 
reside permits the medical use of cannabis.53,54 
Moreover, those who are daily or near-daily adult 
cannabis users without a college degree spend an 
average of almost 9 per cent of their household 
income on cannabis, while median past-month 
cannabis users spend on cannabis nearly the same 
amount as a person who smokes one pack of 
cigarettes a day spends on cigarettes for more details 
about cannabis use in the United States, see the 
following section.55
In Oceania, cannabis use in Australia increased 
slightly between 2007 and 2013, from an annual 
prevalence of 9.1 per cent to 10.2 per cent of the 
population age 14 years and older, although that 
was still significantly below the level reported in 
1998 (17.9 per cent). 
52 For more details, see subsequent discussion in this chapter.
53 Wilson M. Compton and others, “Marijuana use and use 
disorders in adults in the USA, 2002-14: analysis of annual 
cross sectional surveys”, Lancet Psychiatry, vol. 3, No. 10 
(2016), pp. 954-964.
54 Steven S. Davenport and Jonathan P. Caulkins, “Evolution 
of the United States marijuana market in the decade of 
liberalization before full legalization”, Journal of Drug Issues, 
vol. 46, No. 4 (2016).
55 Ibid.
Fig. 28 Annual cannabis prevalence rates in  
the United States, the European Union, 
Australia, and at the global level, 1979-
2015
Sources: UNODC, responses to the annual report questionnaire; 
SAMHSA, EMCDDA and the Australian Institute of Health and 
Welfare.
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of cannabis use, such as Finland, have reported an 
increase in cannabis use in recent years and are now 
high-prevalence countries. Other countries in 
Europe that have shown an increase in past-year 
cannabis use in recent years include Bulgaria, 
Czechia and Sweden.57
Decreasing trend in cannabis use  
in England and Wales 
Cannabis use in England and Wales has significantly 
declined over the past two decades. Although the 
annual prevalence of cannabis use remained stable 
between 2009/10 and 2015/16, at around 6.5 per 
cent of the adult population, the past-month preva-
lence of cannabis use decreased by 14 per cent over 
the same period. In 2015/16, less than half (47 per 
cent) of past-month cannabis users reported that 
they used the drug less than once a week, while only 
14 per cent said they used cannabis daily or almost 
daily.58 
57 Ibid.
58 Deborah Lader, ed., Drug Misuse: Findings from the 2015/16 
Crime Survey for England and Wales, 2nd ed., Statistical Bul-
letin 07/16 (London, Home Office, 2016).
Fig. 29 Trends in past-month use of cannabis among adults (aged 15-64 years) in selected  
high-prevalence countries
Source: EMCDDA, Statistical Bulletin, 2016.
Note: The data for the United Kingdom are from England and  
Wales only.
Fig. 30 Trends in cannabis use in England  
and Wales, by age groups, 1996-2015/16
Source: Deborah Lader, ed., Drug Misuse: Findings from the 
2015/16 Crime Survey for England and Wales, 2nd ed., Statistical 
Bulletin 07/16, (London, Home Office, 2016).
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countries in cannabis use among young people.61 
The perceived availability of cannabis and number 
of cannabis-using friends are positively related to 
cannabis use behaviours, while there is a negative 
correlation between perceived risk of harm in using 
cannabis and its actual use. The association between 
perceived cannabis use among peers and cannabis 
use among adolescents is stronger in European coun-
tries where access to cannabis is perceived to be 
difficult. The influence of the immediate social situ-
ation seems to be more strongly associated with 
cannabis use among 15-16 year olds than are distal 
influences related to the broader social 
environment.62 
Increase in treatment of cannabis use  
disorders among young adults in Europe
In Europe, there was a 50 per cent increase from 
2006 to 2014 in the number of first-time entrants 
for treatment of cannabis use disorders. The vast 
majority (86 per cent) of people entering treatment 
primarily for cannabis use disorders were aged 34 
years or younger, with the mean age being 25 
61 Daniela Piontek and others, “Individual and country-level 
effects of cannabis-related perceptions on cannabis use: a 
multilevel study among adolescents in 32 European coun-
tries”, Journal of Adolescent Health, vol. 52, No. 4 (2013), 
pp. 473 -479.
62 Ibid.
Cannabis use is higher among younger  
age groups than older age groups, but it  
is increasing among older age groups
In England and Wales, there is a higher rate of can-
nabis use among young adults aged 16-19 years and 
those aged 20-24 years than among the older age 
groups, although both past-year and past-month 
prevalence have decreased significantly among young 
adults since 1996. Higher levels of cannabis use in 
the past-year were also reported among those adults 
who consumed alcohol three or more days a week 
in the past month, were unemployed or economi-
cally inactive, had a lower perception of risk of harm, 
as well as among those who visited nightclubs or 
bars/pubs on four or more occasions in the past 
month. While overall cannabis use is low among 
the older age groups (45-54 years and 55-59 years), 
there has been a significant increase among those 
age groups since 1996. Reflecting the ageing cohort 
of cannabis users that reported relatively higher can-
nabis use in the past, the past-year prevalence of 
cannabis use among 45-54 and 55-59 year olds has 
increased significantly: from 1.4 per cent and 0.5 
per cent, respectively, in 1996, to 2.3 per cent and 
1.5 per cent in 2015/16.59 
Cannabis use among 15-16 year olds has 
declined in Europe
In 2015, the annual prevalence and past-month 
prevalence of cannabis use among 15-16 year olds 
in Europe was reported to be 13 per cent and 7 per 
cent, respectively;60 on average, that age group had 
used cannabis 8 or 9 times in the past 12 months. 
Lifetime prevalence of cannabis use among adoles-
cents varies from country to country, ranging from 
37 per cent in Czechia and 31 per cent in France to 
7 per cent in both Sweden and Norway. Contrary 
to the trends in the adult population, a decrease in 
the prevalence of cannabis use among adolescents 
was observed in Czechia, Denmark, Finland and 
France. 
In Europe, a number of factors may play a signifi-
cant role in determining the varying trends between 
59 Ibid.
60 EMCDDA and European School Survey Project on Alcohol 
and Other Drugs, ESPAD Report 2015: Results from the 
European School Survey Projects on Alcohol and other Drugs 
(Lisbon, 2016).
Fig. 31 Trends in cannabis use among 15-16 
years old in Europe
Source: ESAPD Report 2015.
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years.63 This increase in treatment of cannabis use 
disorders can be attributed to the availability of more 
harmful and higher-potency cannabis products —
which are in turn associated with an increase in the 
severity of dependence and disorders — as well as 
to an increase in the availability of treatment and 
referral practices.64, 65, 66, 67 
63 EMCDDA, “Perspectives on drugs: characteristics of fre-
quent and high-risk cannabis users” (Lisbon, 2013).
64 T. P. Freeman and A. R. Winstock, “Examining the profile 
of high-potency cannabis and its association with severity of 
cannabis dependence”, Psychological Medicine, vol. 45, No. 
15 (2015), pp. 3181-3189.
65 EMCDDA, European Drug Report: Trends and Developments 
2016. 
66 Jonathan Schettino and others, Treatment of Cannabis-
related Disorders in Europe, EMCDDA Insights Series No. 
17 (Luxembourg, Publications Office of the European 
Union, 2015).
67 See World Drug Report 2016.
Developments in measures regulating 
recreational cannabis use in the 
United States and Uruguay 
This section reviews trends in cannabis use in the 
United States, where there has been state-level legali-
zation of cannabis cultivation and sale for recreational 
use in some states and for medical use of cannabis 
in others. The World Drug Report 2016 looked at 
the outcome of cannabis legislation in terms of 
developments in public health, public safety, crimi-
nal justice and cannabis markets. This section 
presents some further developments in cannabis 
legislation in the United States and, in particular, 
reviews the extent of exposure of the adult and youth 
populations to cannabis, as well as the interplay 
between the use of cannabis for recreational and 
medical purposes. The section also provides a brief 
update on the status of implementation of cannabis 
regulation in Uruguay.
Fig. 32 Trends in cannabis use among 15-16 year olds in selected countries
Source: ESAPD Report 2015.
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now licensing or are in the process of developing 
licensing schemes to enable for-profit companies to 
produce, market and sell a wide range of cannabis 
products. All of the states that have legalized can-
nabis use had prior measures allowing the medical 
use of cannabis. 
The regulations that allow the sale and personal use 
of cannabis across the different jurisdictions 
permitting such measures differ in their provisions 
as well as in their implementation, as summarized 
in the annex of this booklet. Nevertheless, the states 
that voted in favour of the cultivation, sale and 
personal possession of cannabis for recreational use 
in 2016 have some measures that are similar to those 
passed by the four states that had previously 
permitted recreational cannabis use. These measures 
include: the establishment of a regulatory authority 
and a commercial system of production and supply 
Recent developments in the United States
In 2016, voters in California, Maine, Massachusetts 
and Nevada voted to allow the legalization of can-
nabis for recreational use in their jurisdictions, while 
voters in one state rejected the proposition to legal-
ize cannabis cultivation and use. The approved 
measures allow adults aged 21 years and older in 
those four states to possess cannabis for personal use 
and to grow cannabis plants at home. The total 
number of state-level jurisdictions that now allow 
use of cannabis for recreational purposes has grown 
to eight, plus the District of Columbia.68, 69 Of 
much greater importance is that all those jurisdic-
tions, not including the District of Columbia, are 
68 Home cultivation is not allowed in the State of Washing-
ton. The number of plants allowed in each state varies. 
69 National Conference of State Legislatures (www.ncsl.org).
Preferences and patterns of use of plant-based cannabis and synthetic 
cannabinoids
The emergence of synthetic cannabinoid receptor agonist sold 
under names such as “Spice” and “K2”, as new psychoactive 
substances, was first reported in 2004 and they have since 
been increasingly reported in different parts of the world. 
Synthetic cannabinoids comprise different products with 
chemical structures dissimilar to tetrahydrocannabinol (THC) 
(the principle psychoactive constituent of natural cannabis). 
Effects of synthetic cannabinoid receptor 
agonists
There is growing recognition and reporting of the harm asso-
ciated with intoxication with synthetic cannabinoids, which 
results in emergency room visits. The symptoms include tachy-
cardia, psychosis, agitation, anxiety, breathing difficulties and 
seizures. The literature also shows that the use of synthetic 
cannabinoids has unpredictable negative psychological and 
physiological effects. Intoxication with some forms of syn-
thetic cannabinoids can have severe effects; for instance, 
in an outbreak in New York, people reported experiencing 
“zombie-like” severe depressant effects after intoxication 
with the synthetic cannabinoid AMB-FUBINACA. 
Experiences of cannabis users
The self-reported experiences of cannabis users who had 
recently used synthetic and natural cannabis show that almost 
all recent synthetic cannabinoid users reported that they had 
used natural cannabis, which they preferred over synthetic 
cannabinoids and used for a greater number of days. The 
use of synthetic cannabinoids is associated with more overall 
negative effects than the use of natural cannabis, including 
greater effects on the lungs, hangover effects and a greater 
level of anxiety and paranoia, as reported by users. Among 
those cannabis users, natural cannabis was considered to pro-
duce more memory impairment than synthetic cannabinoids, 
and was perceived to be more addictive. Natural cannabis 
was, however, considered a more consistent product than 
synthetic cannabinoids. 
Overall, synthetic cannabinoids represent a diverse group of 
potent psychoactive compounds that are considered a substi-
tute for natural cannabis but may result in acute intoxication 
and have long-term negative effects on health. Many cannabis 
users, such as those in prison settings, may substitute cannabis 
with synthetic cannabinoids to avoid sanctions (for details, see 
booklet 4 of this report). However, it cannot be concluded that 
the untoward or undesirable effects of synthetic cannabinoid 
receptor agonists will limit their uptake or use. 
Sources: 
Adam R. Winstock and Monica J. Barrat, “Synthetic cannabis: A 
comparison of patterns of use and effect profile with natural 
cannabis in a large global sample”, Drug and Alcohol Depend-
ence, Volume 131, Issues 1–2, 1 July 2013, Pages 106-111.
Adam R. Winstock and Monica J. Barrat, “The 12-month preva-
lence and nature of adverse experiences resulting in emergency 
medical presentations associated with the use of synthetic can-
nabinoid products”, Human Psychopharmacology: Clinical and 
Experimental, July 2013, Volume 28, Issue 4, Pages 390-393.
Tracy L. Brewer and Margie Collins, “A review of clinical mani-
festations in adolescent and young adults after use of synthetic 
cannabinoids”, Journal for specialists in Pedriatic Nursing, April 
2014, Volume 19, Issue 2, p 119-126.
Axel J Adams and others, “'Zombie' Outbreak Caused by the 
Synthetic Cannabinoid AMB-FUBINACA in New York”, New 
England Journal of Medicine, 2017; 376:235-242 January 19, 
2017 DOI: 10.1056/NEJMoa1610300.
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voted for measures to allow medical cannabis. In 
April 2017, West Virginia also passed legislation, 
making a total of 29 states that now have compre-
hensive laws allowing the production, sale and use 
of cannabis for medical conditions. These include 
the states with measures allowing the production 
and sale of cannabis for recreational use. In the Dis-
trict of Columbia, the law allows patients to obtain 
cannabis for medical use only from a dispensary 
licensed by the District’s Health Department and 
does not allow patients or their caregivers to grow 
cannabis. A further 16 states have laws that allow 
the use of products containing low THC levels and/
or high cannabidiol (CBD) levels for medical con-
ditions such as epileptic seizures or seizure 
disorders.72 
The evaluation of the impact of the measures allow-
ing the commercial production, sale and recreational 
use of cannabis on health, criminal justice and other 
outcomes requires regular monitoring over time, 
and it may take years to determine their long-term 
effect on cannabis use and associated harm among 
adults, as well as their influence on cannabis use 
72 National Conference of State Legislatures, “State medical 
marijuana laws”, 21 April 2017. Available at www.ncsl.org/
research/health/state-medical-marijuana-laws.aspx.
by private enterprises; taxation at retail and, in some 
jurisdictions, at the production or cultivation levels; 
certain restrictions on advertisements; packaging 
and labelling restrictions on edibles; and measures 
concerning health and safety standards. California, 
Maine, Massachusetts and Nevada also allow 
on-premises consumption of cannabis at retail or 
specially licensed establishments.70 As it is partly 
within the federal territory, the District of Columbia 
allows “home grown and home use” because people 
can still be arrested for possession of cannabis in the 
federal territory.71 Many issues remain unresolved. 
The legislation that was approved in most of these 
states did not set a maximum limit on THC content, 
whereas states such as Oregon have since done so; 
other states such as California are in the rule-making 
process for the implementation of cannabis 
legislation. 
In the 2016 election, voters in four other states, 
Arkansas, Florida, Montana and North Dakota, 
70 BOTEC Analysis, “Cannabis report: the 2016 election and 
ballot initiatives”, 26 October 2016. Available at http://
botecanalysis.com/cannabis-the-election/; accessed 12 May 
2017.
71 Department of Health of the District of Columbia, “Mari-
juana in the District of Columbia”, LaQuandra S. Nesbitt 
and others, eds. (July 2016).
Map 3 Jurisdictions in the United States that allow recreational use, medical use of cannabis and 
those that allow no access to cannabis
Source: Based on information from the National Conference of State Legislatures (NCSL) as of 12 May 2017.
Notes: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations.
TX
CA
MT
AZ
ID
NV
NM
CO
IL
OR
UT
KS
WY
IANE
SD
MN
ND
OK
FL
WI
MO
WA
AL GA
AR
LA
MI
IN
PA
NY
NC
MS
TN
VA
KY
OH
SC
ME
WV
VT
NH
MD
NJ
MA
CT
DE
RI
HI
AK
Recreational
Medical
Limited medical
No access laws
48
W
O
RL
D
 D
R
U
G
 R
EP
O
RT
 2
01
7
factors.74 One example of these limitations is the 
comparison of trends in the perceived risk of can-
nabis use in the states that have, and those that have 
not, legalized cannabis. Risk perceptions of harm 
negatively influence cannabis use behaviours and 
74 Wayne Hall and Megan Weier, “Has marijuana legalization 
increased marijuana use among US youth”, JAMA Paediat-
rics, Vol. 171, No. 2 (February 2017), pp. 116-118.
Medical marijuana in the United States
Many countries have regulations that allow the use of can-
nabinoid-based medications. Similar to the approval of any 
pharmaceutical product, the approval of cannabinoid-based 
medications typically follows an established protocol in which 
clinical trials have proved the preparation to be effective for 
determined conditions and recommendations are made on dos-
ages and conditions for use. In the United States, the approval 
of cannabis for medical purposes has followed a more com-
plex pattern. The United States Food and Drug Administration 
(FDA), the federal agency in charge of approving medications 
for the United States market, has so far approved three non-
botanical formulations based on the molecular structure of 
cannabinoids — dronabinol, a synthetic 9-tetrahydrocannabi-
nol, its oral capsule and liquid formulations and, nabilone, 
a synthetic analogue of THC for oral use. Several additional 
cannabinoid-based medications — Sativexa (composed of THC 
and CBD), Epidiolex (cannabidiol oil) and another CBD oral 
solution were each granted Fast Track designations by FDA 
to facilitate development and expedite FDA review of their 
respective therapeutic indications.b According to the United 
States National Academies of Sciences, Engineering and Medi-
cine, in California, clinical and preclinical trials of cannabinoids 
were initiated in 2000, with 13 out of the 21 approved studies 
completed. In Colorado, research on the medicinal benefits of 
cannabis products was initiated in 2015.c 
As of May 2017, independent of the approval of pharmaceuti-
cal preparations, the use of cannabis products, such as herb (for 
vaporizing), extracts (tinctures), edibles and capsules for medical 
purposes, has been introduced in 29 states through statutory 
laws or constitutional amendments as voter initiatives, either 
through direct ballot or through state legislatures.c Although 
most states currently have, or had in the past, a therapeutic 
research programme, the cannabis products that are dispensed 
have not been developed through rigorous scientific processes. 
No products “developed” from state research programmes 
have received FDA approval. While the conditions that allow 
medical use of cannabis vary in each of those 29 states, most 
of the states require that a physician submit a signed form 
to the state regarding a person’s eligibility for such use and 
most have a programme for registering patients for medical 
use of cannabis based on the physician’s recommendation. In 
California and Maine, however, the registration of patients is 
considered voluntary or optional, whereas the state of Wash-
ington has no system for the registration of medical cannabis 
users in place. Many states such as California allow medical 
use of cannabis for a broad set of indications that may include 
any serious medical condition for which cannabis could provide 
relief.d,e In some states the law requires the state to produce 
and distribute cannabis products, including plants (for vapor-
izing), tinctures and capsules, in clinical settings, while in other 
states doctors are required to prescribe cannabis products and 
monitor the results. However, these measures have proved 
unworkable as they require physicians or clinics to violate fed-
eral law. While the states that allow medical use of cannabis 
have passed legislation regulating the production, sale and 
dispensation of medical cannabis, there are differences in the 
manner and length of time in which these measures have 
been implemented. 
Although there are plans by the National Institute on Drug 
Abuse at the national level to provide a range of clinically 
relevant cannabis products for research, there are significant 
regulatory barriers for conducting such research on the health 
effects of different cannabis products. Also, those products 
need to be comparable with or relevant to the range of medi-
cal cannabis products used by consumers in the states where 
use of medical cannabis is permitted.f In most of those states 
the range of products currently available for medical purposes 
has not gone through the rigours of research in product devel-
opment, clinical trials determining health effects, optimum 
dosage, standardized dosing, methods of administration and 
overall quality control measures employed for all pharmaceuti-
cal products. 
a  As of September 2016, Nabiximols has been launched in 15 
countries and approved in a further 12.
b  National Academies of Sciences, Engineering, and Medicine, The 
Health Effects Of Cannabis And Cannabinoids: The Current State 
of Evidence and Recommendations for Research (Washington, D. 
C, National Academies Press, 2017).
c  Marijuana Policy Project, “State-by-State medical marijuana 
laws: how to remove the threat of arrest, 2015” (Washington, D. 
C, 2016).
d  Rosalie L. Pacula and others, “State medical marijuana laws: 
understanding the laws and their limitations”, Journal of Public 
Health Policy, vol. 23, No. 4 (2002), pp. 23, 413-439.
e  Fairman, J, B., “Trends in registered medical marijuana partici-
pation across 13 US states and District of Columbia”, Drug and 
Alcohol Dependence, 159 (2016) 72-79.
f  National Academies of Sciences, Engineering, and Medicine, The 
Health Effects of Cannabis and Cannabinoids.
among adolescents.73 Indeed, since the effects of 
changes in one state spill over and affect other states, 
there remain limitations to the evaluation of the 
effects of these policy changes due to extraneous 
73 Wayne Hall and Megan Weier, “Assessing the public health 
impacts of legalizing recreational cannabis use in the USA”, 
Clinical Pharmacology and Therapeutics, vol. 97 (June 
2015), pp. 607-615.
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use observed among adults has been associated with 
those who perceive no risk of harm from cannabis 
smoking; among those from lower socioeconomic 
groups; and those residing in a jurisdiction that per-
mitted the medical use of cannabis.78, 79 According 
to data from the National Survey on Drug Use and 
Health (NSDUH), the past-month prevalence of 
cannabis use among the population aged 12 years 
and older in the United States increased from 6.2 
per cent in 2002 to 8.3 per cent in 2015, with an 
estimated 22 million people aged 12 years and older 
being current (past-month) cannabis users in 
2015.80 Since 2008 there has been a consistent 
year-on-year increase in cannabis use among the 
78 Ibid.
79 Davenport and Caulkins, “Evolution of the United States 
marijuana market”.
80 Center for Behavioral Health Statistics and Quality, “Key 
substance use and mental health indicators in the United States: 
Results from the 2015 National Survey on Drug Use and 
Health” (HHS Publication No. SMA 16-4984, NSDUH 
Series H-51). Retrieved from http://www.samhsa.gov/data/.
are considered a protective factor; however, risk per-
ceptions among the general population have 
declined over the years in the entire United States 
due to a number of factors, which include: the spill-
over effects of policy debates over legalization; an 
increase in cannabis use, which is perceived to be 
less risky among users; and the media coverage of 
the medical use of cannabis in many states.75 In 
addition, legislation and contexts vary considerably 
across states that have passed legislation legalizing 
recreational and medical cannabis. Therefore, gen-
eral analysis comparing states that allow recreational 
markets with those that do not has limitations.
The following sections review some of these issues 
in an attempt to understand the influence of meas-
ures regulating cannabis production and use on 
behaviours related to cannabis use in the general 
population. 
The approval of state-level cannabis regu-
lations has occurred in an environment of 
overall increase in cannabis use across the 
United States
It is challenging to measure the health impact of the 
new regulations implemented by some of the states 
in the United States since cannabis laws have 
changed in concomitance with a series of other ele-
ments that have changed the cannabis market not 
only in the concerned states, but across the entire 
United States. Overall, cannabis use has increased 
in the United States among adults aged 18 years and 
older since 2002.76 This has occurred in an environ-
ment with decreasing perceptions of risk of harm 
from cannabis use, in which some states have per-
mitted the medical use of cannabis, and with 
extensive media coverage of state level debates 
around the medical use or legalization of cannabis 
for recreational use. 
The increase in cannabis use has been among heavy 
users and those aged 26 years or older, in particu-
lar.77 The high prevalence and frequency of cannabis 
75 Ibid.
76 Alejandro Azofeifa and others “National estimates of  
marijuana use and related indicators – National Survey on 
Drug Use and Health”, United States, 2002–2014. MMWR 
Surveillance Summaries 2016; 65, No. SS-11, pp.1-25.  
Available at http://dx.doi.org/10.15585/mmwr.ss6511a1.
77 Wilson M. Compton and others, “Marijuana use and use 
disorders in adults in the USA, 2002-14: analysis of annual 
cross sectional surveys”, Lancet Psychiatry 2016; 3: 954-64.
Fig. 33 United States: cannabis use patterns, risk  
perception, availability and medical cannabis 
among the population aged 18 years and 
older, 2002-2015 
Sources: Key Substance Use and Mental Health Indicators in the 
United States: Results from the 2015 National Survey on Drug Use 
and Health,  
and earlier surveys and adapted from Compton and others, “Mari-
juana use and use disorders in adults in the USA, 2002-14: analysis 
of annual cross sectional surveys”, Lancet Psychiatry 2016; 3: 954-64.
Note: Compton and others analysed the trends in cannabis use from 
2002-2014.
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Fig. 34 Cannabis use in the past month among the population aged 12 years and older in the 
United States as a whole, in states with measures allowing recreational cannabis market, 
and other selected states, 2002-2015 
Source: Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug 
Use and Health, earlier surveys and SAMHSA State level estimates for the different years. Except for 2002, the state level esti-
mates are presented as two-year averages. Alaska, Colorado, California, Maine, Nevada and Oregon had medical cannabis in 
2000 or earlier. 
precede any measures to legalize cannabis. The 
increase in cannabis use, although not in all states, 
can also be seen in those states that have not legal-
ized recreational use of cannabis. Overall, the 
increasing trend in cannabis use is considered to be 
associated with provisions of medical cannabis — 
with the evidence suggesting an overall reciprocal 
relationship between social attitudes and cannabis 
use patterns.81 Beginning with California in 1996 
and followed by Alaska, Oregon and Washington 
in 1998, 12 jurisdictions had made provisions for 
the medical use of cannabis by 2007. The cumula-
tive effects of these policy changes might have led 
to changes in the risk perceptions of harm from 
cannabis use among the adult population and a sub-
sequent increase in cannabis use.82
81 Rosalie L. Pacula and others, “Assessing the effects of  
medical marijuana laws on marijuana use: the devil is in the 
details”, Journal of Policy Analysis and Management, vol. 34, 
No. 1 (2015), pp. 7-31.
82 Compton and others, “Marijuana use and use disorders in 
adults in the USA, 2002-14”.
population aged 12 years and older, particularly in 
those states that currently allow the production and 
sale of cannabis for recreational use among adults. 
In those states, rates of cannabis use higher than the 
national average have been observed, although they 
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Fig. 35 United States: trends in cannabis 
use initiation in the past year, by age 
groups, 2002-2015
Source: Elaborated from NSDUH presented in Rachel N. Lipari 
and others, “Risk and protective factors and estimates of sub-
stance use initiation: results from the 2015 National Survey on 
Drug Use and Health” (SAMHSA, October 2016).
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significantly among the population aged 26 years 
and older from 5.8 per cent to 7.2 per cent over the 
period 2004-2013. Among the younger age groups 
(12-17 years and 18-25 years), however, changes in 
the prevalence of non-medical cannabis use were 
not statistically significant and not considered to be 
related to the measures that allow the use of can-
nabis for medical purposes.86 Cannabis users living 
in the states that have measures allowing medical 
cannabis use also reported a higher perception of 
easy availability of cannabis. Although this percep-
tion has not changed among the younger age groups 
(12-17 and 18-25) since medical cannabis laws were 
introduced in those states, there has been a signifi-
cant increase in the perceived easy availability of 
cannabis among those aged 26 years or older.87 Past-
month recreational cannabis use and the perceptions 
of easy availability of cannabis have increased sig-
nificantly in all the older groups since the passing 
of medical cannabis laws.88, 89
Difference between recreational and medi-
cal users in the United States
In March 2016, around 1.2 million people were 
estimated to be registered for medical cannabis cards 
across the United States,90, 91 which corresponds to 
eight medical cannabis patients per 1,000 popula-
tion. The highest rates of registration per 1,000 
population were in Colorado (19.8), California 
(19.4), Washington (19.2) and Oregon (19.2); states 
with the longest standing medical cannabis provi-
sions.92 However, these estimates should be 
considered with caution as several states do not 
maintain registries of medical cannabis.
86 Ibid.
87 Ibid.
88 Ibid.
89 Alejandro Azofeifa and others “National estimates of mari-
juana use and related indicators – National Survey on Drug 
Use and Health”.
90 Estimated number of medical cannabis users registered in 
21 out of 23 states and the District of Columbia that have 
medical cannabis laws.
91 ProCon.org, “Number of legal medical marijuana patients 
(as of 1 March 2016)”. Available at http://medicalmari-
juana.procon.org/view.resource.php?resourceID=005889 
(last updated on 3 March 2016).
92 The medical cannabis law in California was passed in 1996, 
in Oregon and Washington in 1998 and in Colorado in 
2000.
Medical cannabis use regulations may  
have influenced the risk of adult non- 
medical cannabis use
Compared with the other states, those that allow 
medical use of cannabis have higher prevalence of 
past-month non-medical use of cannabis in all age 
groups. But laws that permit the medical use of can-
nabis appear, as yet, to have had little effect on the 
prevalence rate of recreational use of cannabis among 
adolescents, while they may have influenced the risk 
of non-medical cannabis use among the adult popu-
lation.83, 84, 85 
In the states that allow medical cannabis use, past-
month non-medical use of cannabis increased 
83 Melanie M. Wall and others, “Prevalence of marijuana use 
does not differentially increase among youth after states pass 
medical marijuana laws: commentary on Stolzenberg et al. 
(2015) and reanalysis of US National Survey on Drug Use 
in Households data 2002–2011”, International Journal of 
Drug Policy, vol. 29 (2016), pp. 9-13.
84 Deborah S. Hasin and others, “State medical marijuana 
laws and adolescent marijuana use in the United States: 
1991-2014”, Lancet Psychiatry, vol. 2, No. 7 (July 2015), 
pp. 601-608.
85 Silvia S. Martins and others, “State-level medical marijuana 
laws, marijuana use and perceived availability of marijuana 
among the general US population”, Drug and Alcohol 
Dependence, vol. 1 (December 2016), pp. 26-32.
Fig. 36 Past-month prevalence of non-medical 
cannabis use among older age groups, 
prior to and following the legalization 
of medical cannabis use, 2004-2013
Source: Silvia S. Martins and others, “State-level medical  
marijuana laws, marijuana use and perceived availability of 
marijuana among the general US population”, Drug and  
Alcohol Dependence, vol. 1 (December 2016), pp. 26-32.
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In many jurisdictions the medical cannabis market 
is used for both medical and recreational purposes. 
According to a national consumer panel survey of 
adults in 2014, more than one third of the 
respondents reported current use of medical cannabis 
for both medical and recreational purposes.98 Those 
who use medical cannabis solely for medical purposes 
tend to use it for alleviating perceived medical 
symptoms in addition to alleviating anxiety, 
depression or other psychological symptoms.99 
Recreational cannabis users who access the medical 
cannabis market may be a heterogeneous group who 
use cannabis for different motives, including 
experimentation, coping and other social or 
psychological reasons.100, 101 NSDUH data from 
2013 and 2014 show that medical cannabis use was 
associated with the older age groups, poorer health 
status and with anxiety disorder.102 Furthermore, 
among people reporting medical cannabis use the 
prevalence of daily or almost daily cannabis use was 
three times higher than among those reporting 
recreational use, although the same proportion (11 
per cent and 10 per cent, respectively) of individuals 
who used cannabis recreationally or medically met 
the criteria for cannabis use disorders. Both groups 
had similar levels of depression, although medical 
cannabis users were less likely to meet the criteria 
for alcohol use disorder or to use other illicit drugs. 
Similarities in correlates of medical and non-medical 
cannabis users, especially co-occurrence of psychiatric 
conditions and other substance use, suggest that 
some cannabis users may access medical cannabis 
without a diagnosed medical need.103, 104
98 Gillian L. Schauer, and others, “Toking, Vaping, and Eating 
for Health or Fun Marijuana Use Patterns in Adults, U.S., 
2014” American Journal of Preventive Medicine, vol. 50, No. 
1, pp. 1-8 (January 2016).
99 Wilson M. Compton and others, “Use of marijuana for 
medical purposes among adults in the United States”, JAMA, 
vol. 317, No. 2 (2017), pp. 209-211.
100 Lewei A. Lin and others, “Comparing adults who use can-
nabis medically with those who use recreationally: results 
from a national sample”, Addictive Behaviors, vol. 61 
(2016), pp. 99-103.
101 Wilson M. Compton and others, “Use of marijuana for 
medical purposes among adults in the United States”, 
JAMA, vol. 317, No. 2 (2017), pp. 209-211. 
102 Ibid.
103 Ibid.
104 Marcel O. Bon-Miller and others, “Self-reported cannabis 
use characteristics, patterns and helpfulness among medi-
cal cannabis users”, American Journal of Drug and Alcohol 
Abuse, vol. 40, No. 1 (2014), pp. 23-30. 
According to the National Academies of Sciences, 
Engineering and Medicine, there is evidence that 
medical use of cannabis-based products is effective 
for a limited number of conditions93 (see the annex 
of this booklet). However, it is likely that in the 
medical cannabis system in place in the jurisdictions 
in United States, not all of the people who have a 
condition that may qualify for medical cannabis 
products are registered; conversely, many patients 
who are registered may not even have a medical 
condition.94 Studies also suggest that younger reg-
istrants may be more likely to engage in the diversion 
of medical cannabis or may only be registered in 
order to circumvent the laws prohibiting recreational 
cannabis use, although the exact extent of this is not 
known.95 Trends in the characteristics of people 
participating in medical cannabis programmes can 
help understand the public health and policy issues 
surrounding access to medical cannabis, although 
this information is not available uniformly in all 
states with such programmes.96 Based on data from 
the states where multiple data points on registered 
medical cannabis use were available, the majority 
(between 50 per cent and 75 per cent) of patients 
registered in medical cannabis programmes were 
male. The age distribution of participants in eight 
states shows that a large proportion of registrants 
were in their 40s and 50s. However, this was differ-
ent in states such as Colorado and Arizona where 
young adults (18-30 years) made up around one 
quarter of the participants in medical cannabis 
programmes.97 
93 The Health Effects of Cannabis and Cannabinoids. 
94 “Number of legal medical marijuana patients”. Available 
at http://medicalmarijuana.procon.org/view.resource.
php?resourceID=005889. 
95 Fairman, “Trends in registered medical marijuana participa-
tion”. 
96 Ibid.
97 Ibid.
In the United States, the National Academies of Sciences, Engi-
neering and Medicine recently published The Health Effects of 
Cannabis and Cannabinoids: the Current State of Evidence and 
Recommendations for Research. A summary of NAS evidence 
of the therapeutic effects of products based on cannabis and 
cannabinoids and the statistical association between cannabis 
use and the incurrence of health conditions can be found in 
the annex of this booklet.
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Washington after cannabis had been legalized. In 
Colorado, cannabis use among eighth and tenth 
graders remained stable or decreased, while in states 
that had not legalized recreational cannabis use it 
declined. Past-month cannabis use among twelfth 
graders remained at similar levels in Colorado, 
Washington and in states that had not legalized rec-
reational cannabis use. However, the data used in 
this study were not representative at state level. Dif-
ferent data from the State Healthy Youth Survey 
showed that the prevalence of cannabis use among 
tenth graders remained unchanged in Washington 
during the period 2001-2014.109 
Different trends in different states could relate to 
exposure to the medical cannabis market. The 
expansion of for-profit dispensaries in Colorado had 
effectively legalized the commercial supply of can-
nabis before the laws were passed to allow for 
recreational use. Cannabis use among youth may 
not have changed as they would have already formed 
their attitudes and beliefs about cannabis use and 
were therefore less likely to be influenced by legali-
zation measures. 
Earlier studies found no differences in rates of 
change in cannabis use among youth or in the per-
ceived risk of cannabis use between states that allow 
medical cannabis use and those that do not.110, 111 
It is not conclusive whether legalizing cannabis for 
recreational use among adults would influence its 
use among adolescents,112 and further quality data 
and analysis representative at state level of long-term 
trends are required to address the question. 
109 Anar Shah and Mandy Stahre, “Marijuana use among 10th 
grade students – Washington, 2014”. Morbidity and Mortal-
ity Weekly Report, 65 (30 December 2016), pp. 1421-1424. 
DOI: http://dx.doi.org/10.15585/mmwr.mm655051a1
110 Melanie M. Wall and others, “Adolescent marijuana use 
from 2002 to 2008: higher in States with medical mari-
juana laws, cause still unclear”, Annals of Epidemiology, vol. 
21, No. 9 (September 2011) pp. 714-716.
111 Sam Harper, Erin C. Strumpf and Jay S. Kaufman, “Do 
medical marijuana laws increase marijuana use? Replication 
study and extension”, Annals of Epidemiology, vol. 22, No. 3 
(March 2012), pp. 207-212.
112 Cerdá and others “Association of state recreational mari-
juana laws with adolescent marijuana use”.
Has cannabis use among high school  
students changed in states that have  
legalized recreational cannabis use? 
One important element in understanding the impact 
of legalizing recreational use of cannabis is to 
examine the extent to which such measures have 
influenced and affected the use of cannabis by 
adolescents. Current research on the subject remains 
inconclusive, however. National data show that, in 
contrast to the increase in cannabis use among 
adults, the prevalence of past-year and past-month 
cannabis use across the United States has declined 
among 8th and 10th grade high school students and 
has remained unchanged among twelfth graders in 
the past five years or so. Similarly, current daily use 
or near daily use has declined among 8th and 10th 
graders and has remained at similar levels among 
twelfth graders over the same period.105
Some studies have looked at state level data and 
concluded that past-year cannabis use is higher 
among twelfth grade students in states with laws 
permitting the use of cannabis for medical purposes 
than in states without such laws (38.3 per cent vs. 
33.3 per cent), although these studies suggest that 
these differences precede those measures, presum-
ably, in part, because states that allow the use of 
medical cannabis have had very liberal medical can-
nabis laws.106, 107 
A study based on data from the Monitoring the 
Future survey compared trends in cannabis use 
among high school students in Colorado and Wash-
ington over the periods 2010-2012 and 2013-2015 
with those in states that had not, at that time, legal-
ized recreational use of cannabis.108 The study 
showed that there was an increase in cannabis use 
among eighth and tenth graders in the state of 
105 Lloyd D. Johnston and others, Monitoring the Future 
National Survey Results on Drug Use, 1975-2016: Over-
view, Key Findings on Adolescent Drug Use (Ann Arbor, 
Michigan, University of Michigan Institute for Social 
Research, 2017).
106 United States, National Institute on Drug Abuse, Moni-
toring the Future Survey: High School and Youth Trends 
(revised December 2016).
107 Deborah Hasin and others, “State medical marijuana laws 
and adolescent marijuana use in the United States: 1991-
2014.
108 Magdalena Cerdá, and others “Association of state recrea-
tional marijuana laws with adolescent marijuana use”, JAMA 
Pedriatic, vol. 171, No. 2 (February 2017).
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recreational use of cannabis and those that do not 
have such measures in place. However, the policy 
changes allowing the recreational use of cannabis 
may potentially increase cannabis use disorders 
among adults in the longer term.116
Cannabis use disorders are higher among those 
adults (18 years or older) without a high school 
diploma, among adults in part-time employment 
or not employed due to disability, among those who 
have never married, among those who have specific 
substance use disorders (tobacco, alcohol, cocaine 
and prescription opioids) and among adults who 
have experienced a major depressive episode.117 
Cannabis regulation in Uruguay:  
provisions and recent developments
In 2013, the Government of Uruguay approved 
legislation (Law No. 19.172) regulating the cultiva-
tion, production, dispensing and use of cannabis 
for recreational purposes.118 As the provisions regu-
lating the recreational use of cannabis are being 
implemented gradually it is, however, too early to 
detect any effects from the regulations implemented 
to date. 
116  bid.
117 Compton and others, “Use of marijuana for medical  
purposes among adults in the United States”, pp. 209-211.
118 The main elements of regulation are given in the annex of 
this booklet.
Has problematic use of cannabis increased 
as a result of increased cannabis use in the 
United States?
It has been noted that in the current environment 
of lower risk perceptions of harm from cannabis use 
and measures allowing the medical or non-medical 
use of cannabis, the number of new cannabis users 
among older adults, and/or of older adults resum-
ing cannabis use, has increased. However, trends in 
cannabis use disorders are mixed. At around 1.5 per 
cent, the prevalence of cannabis use disorders113 
among the adult population (18 years and older) of 
the United States remained stable during the period 
2002-2015, while the proportion of cannabis use 
disorders among regular adult users declined from 
14.8 per cent in 2002 to 11 per cent in 2015.114 
Similar trends could be observed in the population 
aged 12 years and older: the proportion of cannabis 
use disorders among past-year cannabis users 
decreased by almost one third (from 16.7 per cent 
in 2002 to 11.9 per cent) in 2014).115 The overall 
prevalence of cannabis use disorders among the pop-
ulation aged 12 years and older as well as among all 
the other age groups, except for those aged 26 years 
and older, declined during the period 2002-2015. 
It appears that the national trend was driven by large 
declines among the younger age groups, whereas 
adults aged 26 years and older actually experienced 
diverging trends, with increases in the prevalence of 
cannabis use disorders over the past few years. 
There is no significant difference observed in the 
extent of cannabis use disorders among adults in 
the states that have measures for the medical or 
113 Cannabis use disorder, according to the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fifth Edition (DSM-5) 
is defined as a problem-causing pattern of cannabis use 
leading to clinically significant impairment or distress, as 
manifested by at least two distinguishing symptoms (e.g., 
cannabis is taken in larger amounts or for longer periods 
than intended; experience of craving; continued cannabis 
use despite the experience of physical, social, or interper-
sonal problems caused by cannabis use) occurring within a 
12-month period.
114 Data from the National Survey on Drug Use and Health as 
reported in Compton and others, “Marijuana use and use 
disorders in adults in the USA, 2002-14”. 
115 Alejandro Azofeifa, Margaret E Mattson, and others 
“National Estimates of Marijuana Use and Related Indica-
tors — National Survey on Drug Use and Health”, United 
States, 2002–2014. MMWR Surveillance Summaries 2016; 65 
(No. SS-11):1–25. DOI: http://dx.doi.org/10.15585/mmwr.
ss6511a1
Fig. 37 Trends in cannabis use disorders among 
daily or near daily users in the United 
States, by age group, 2002-2015
Source: Key Substance Use and Mental Health Indicators in 
the United States: Results from the 2015 National Survey on 
Drug Use and Health
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Domestic cultivation
Domestic cultivation is meant for personal or shared 
use in a household in which each adult is allowed 
to cultivate up to six cannabis plants for personal 
consumption, with the final product not exceeding 
480 grams in weight per year. The system for the 
registration of domestic cannabis cultivation was 
created in August 2014. Those who had already 
been cultivating cannabis had a period of up to six 
months to register with IRCCA. As of January 2017, 
6,057 individuals had been registered for the domes-
tic cultivation of cannabis – thus the production of 
2,907 kg of cannabis had been authorized up until 
then. 
Cannabis clubs
Cannabis clubs are registered and accredited as “civil 
associations” by the Ministry of Education and Cul-
ture and then registered with IRCCA for the purpose 
of collective cultivation, production and use of can-
nabis among their members. As of January 2017, 
33 cannabis clubs had been registered in the country, 
each one with a minimum of 15 and a maximum 
of 45 adult members, with data about the club and 
Since adopting the legislation, the Government has 
passed a number of additional decrees and ordinances 
concerning the regulation of specific elements such 
as regulating the medical use of cannabis, the mar-
keting of non-medical cannabis through pharmacies, 
as well as the registration of users, marketing and 
dispensation of cannabis for recreational use, etc. 
In accordance with the Uruguayan legislation, 
cannabis for recreational use can be obtained via 
registration with the national Institute for Regulation 
and Control of Cannabis (IRCCA) by opting for 
one of the three options: pharmacies, clubs or 
individual cultivation. Since the adoption of the 
law, some aspects of cannabis regulation have been 
implemented while other aspects, such as 
dispensation through pharmacies and commercial 
production, are being considered with provisions 
for monitoring compliance and controlling 
diversion. Key provisions and recent developments 
in each of these areas are summarized in the 
following sections.119
119 The information in this section is taken from the Institute 
for Regulation and Control of Cannabis.
Fig. 38 Prevalence and proportion of cannabis use disorders among daily or near daily adult (18 
years or older) cannabis users, in the United States, 2002-2015
Sources: Wilson M. Compton and others, “Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual 
cross sectional surveys”, Lancet Psychiatry, vol. 3, No. 10 (2016), pp. 954-964; Alejandro Azofeifa, Margaret E. Mattson and Rob 
Lyerla, “Supplementary material State level data: estimates of marijuana use and related indicators — national survey on drug 
use and health, California, 2002-2014” (Rockville, Maryland, Center for Behavioral Health Statistics and Quality, Substance Abuse 
and Mental Health Services Administration, (2016).
0
2
4
6
8
10
12
14
16
18
0
0.5
1
1.5
2
2.5
3
3.5
4
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Pe
rc
en
ta
ge
 o
f c
an
na
bi
s 
us
e 
di
so
rd
er
s 
am
on
g 
ad
ul
ts
Pr
ev
al
en
ce
 o
f d
ai
ly
 u
se
 a
nd
 c
an
na
bi
s 
us
e 
di
so
rd
er
s a
m
on
g 
ad
ul
ts
United States
Daily or near daily use among adults
Cannabis use disorders among adults
Percentage of cannabis use disorders
among adults
0
2
4
6
8
10
12
14
16
18
0
0.5
1
1.5
2
2.5
3
3.5
4
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Pe
rc
en
ta
ge
 o
f c
an
na
bi
s 
us
e 
di
so
rd
er
s 
am
on
g 
ad
ul
ts
Pr
ev
al
en
ce
 o
f d
ai
ly
 u
se
 a
nd
 c
an
na
bi
s 
us
e 
di
so
rd
er
s a
m
on
g 
ad
ul
ts
United States
Daily or near daily use among adults
Cannabis use disorders among adults
Percentage of cannabis use disorders
among adults
0
2
4
6
8
10
12
14
16
18
0
0.5
1
1.5
2
2.5
3
3.5
4
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Pe
rc
en
ta
ge
 o
f c
an
na
bi
s 
us
e 
di
so
rd
er
s 
am
on
g 
ad
ul
ts
Pr
ev
al
en
ce
 o
f d
ai
ly
 u
se
 a
nd
 c
an
na
bi
s 
us
e 
di
so
rd
er
s a
m
on
g 
ad
ul
ts
United States
Daily or near daily use among adults
Cannabis use disorders among adults
Percentage of cannabis use disorders
among adults
0
2
4
6
8
10
12
14
16
18
0
0.5
1
1.5
2
2.5
3
3.5
4
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Pe
rc
en
ta
ge
 o
f c
an
na
bi
s 
us
e 
di
so
rd
er
s 
am
on
g 
ad
ul
ts
Pr
ev
al
en
ce
 o
f d
ai
ly
 u
se
 a
nd
 c
an
na
bi
s 
us
e 
di
so
rd
er
s a
m
on
g 
ad
ul
ts
United States
Daily or near daily use among adults
Cannabis use disorders among adults
Percentage of cannabis use disorders
among adults
0
2
4
6
8
10
12
14
16
18
0
0.5
1
1.5
2
2.5
3
3.5
4
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Pe
rc
en
ta
ge
 o
f c
an
na
bi
s 
us
e 
di
so
rd
er
s 
am
on
g 
ad
ul
ts
Pr
ev
al
en
ce
 o
f d
ai
ly
 u
se
 a
nd
 c
an
na
bi
s 
us
e 
di
so
rd
er
s a
m
on
g 
ad
ul
ts
United States
Daily or near daily use among adults
Cannabis use disorders among adults
Percentage of cannabis use disorders
among adults
0
2
4
6
8
10
12
14
16
18
0
0.5
1
1.5
2
2.5
3
3.5
4
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Pe
rc
en
ta
ge
 o
f c
an
na
bi
s 
us
e 
di
so
rd
er
s 
am
on
g 
ad
ul
ts
Pr
ev
al
en
ce
 o
f d
ai
ly
 u
se
 a
nd
 c
an
na
bi
s 
us
e 
di
so
rd
er
s a
m
on
g 
ad
ul
ts
United States
Daily or near daily use among adults
Cannabis use disorders among adults
Percentage of cannabis use disorders
among adults
0
2
4
6
8
10
12
14
16
18
0
0.5
1
1.5
2
2.5
3
3.5
4
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Pe
rc
en
ta
ge
 o
f c
an
na
bi
s 
us
e 
di
so
rd
er
s 
am
on
g 
ad
ul
ts
Pr
ev
al
en
ce
 o
f d
ai
ly
 u
se
 a
nd
 c
an
na
bi
s 
us
e 
di
so
rd
er
s a
m
on
g 
ad
ul
ts
United States
Daily or near daily use among adults
Cannabis use disorders among adults
Percentage of cannabis use disorders
among adults
0
2
4
6
8
10
12
14
16
18
20
0
0.5
1
1.5
2
2.5
3
3.5
4
20
02
/0
3
20
03
/0
4
20
04
/0
5
20
05
/0
6
20
06
/0
7
20
07
/0
8
20
08
/0
9
20
09
/1
0
20
10
/1
1
20
11
/1
2
20
12
/1
3
20
13
/1
4
Pe
rc
en
ta
ge
 o
f c
an
na
bi
s 
us
e 
di
so
rd
er
s 
am
on
g 
ad
ul
ts
Pr
ev
al
en
ce
 o
f d
ai
ly
 u
se
 a
nd
 c
an
na
bi
s 
us
e 
di
so
rd
er
 a
m
on
g 
ad
ul
ts
California
Cannabis use disorders among adults
Daily or near daily use among adults
Percentage of cannabis use disorders
among adults
56
W
O
RL
D
 D
R
U
G
 R
EP
O
RT
 2
01
7
pharmacies. Interested parties were required to pro-
vide a detailed plan of production, facilities, varieties 
to be produced, phytosanitary management, records 
and quality control, product packaging and label-
ling conditions. The levels of THC, cannabidiol and 
cannabinol in proposed cannabis varieties have also 
been evaluated. Two enterprises have been granted 
a licence to produce 2 tons of cannabis each for 
distribution through pharmacies. The price for dis-
tribution from the producer to pharmacy has been 
established at $0.90 per gram, which will be adjusted 
annually. The product will be packaged with a maxi-
mum content of 10 g in containers that will preserve 
the product for a minimum of six months. 
Limited scale of legal supply to date
As noted, only 6,057 individuals and 33 clubs with 
up to 45 members can now produce cannabis legally, 
potentially providing legal supply to only around 
7,500 out of the estimated 140,000 past-month 
cannabis users who live in Uruguay. The impact of 
provisions regulating the recreational use of cannabis 
will only be evident after those have been fully 
implemented and will require close monitoring over 
time.
its members being protected. IRCCA has developed 
guidelines for operating conditions, infrastructure 
and other measures relating to cannabis clubs. A 
licence for cannabis cultivation is valid for three 
years, and each club can plant up to 99 cannabis 
plants, with an output proportional to the number 
of club members, and which may not exceed 480 
grams of cannabis per person per year; any excess 
production is taken over by IRCCA. By the end of 
2015, cannabis clubs had declared a total of 23.8 
kg of cannabis produced; in 2016, they declared a 
total of 121.89 kg. 
Sale through pharmacies
The dispensation of cannabis for recreational use 
will be allowed through “first class community phar-
macies”, as defined in the regulations and registered 
with IRCCA for the purpose. Although the dispen-
sation of cannabis has not yet started, by February 
2017, 83 pharmacies had expressed their interest, 
of which 14 had been registered. Pharmacies will 
sell cannabis exclusively to adults (18 years or older) 
who are registered in the system, with the total 
amount sold not to exceed 10 g per person per week 
or 40 g per month. Uruguayan citizenship or per-
manent residency in Uruguay is, however, required 
for registration. At the time of writing, the price of 
cannabis had been set at approximately $1.30 per 
gram, which may be readjusted at the time of 
dispensing. 
Individuals registered for cannabis use 
through pharmacies
As also foreseen in other national laws and regula-
tions, cannabis regulation in Uruguay recognizes 
the need for the protection of the personal data of 
those who are registered for personal cannabis use. 
IRCCA is developing a computer system for user 
registration that will use biometrics for the identi-
fication and validation of users. As foreseen by the 
law, the individual anonymization process will be 
reversible only at the request of a competent judge. 
At the time of writing, no individual had been reg-
istered to obtain cannabis through pharmacies.
Commercial production of cannabis
In August 2014, IRCCA began the process of solic-
iting the interest of potential producers and 
distributors of cannabis for recreational use through 
